Overview

This trial is active, not recruiting.

Condition osteoporosis
Sponsor Centre Hospitalier Régional Metz-Thionville
Start date January 2013
End date January 2019
Trial size 120 participants
Trial identifier NCT02892188, 2013-01Obs-CHRMT

Summary

The purpose of this study is to evaluate the follow-up of the osteoporotic patient by a physician-pharmacist collaboration.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
Respect of treatment and of hygienic dietary measures by patients with a self-questionnaire per medical check
time frame: year 3

Secondary Outcomes

Measure
Qualitative evaluation of the professional adhesion for the follow-up process once a year during the annual meeting
time frame: year 3
Quantitative evaluation of it by the return rate of questionnaires
time frame: year 3

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - older than 18 years old - having an osteoporosis treatment - following a Therapeutical Education for Patient Exclusion Criteria: - opposition for anonymised data gathering

Additional Information

Official title Assessment of the Follow-up of Osteoporotic Patients by a Physician-pharmacist Collaboration
Principal investigator Didier POIVRET, MD
Description Treatments allow decreasing the personal fracture risk from 48% to 85% provided that the treatment period is continued at least 3 to 5 years and that hygienic and dietary measures are applied: optimization of the dietary calcium intakes (much more efficient and less dangerous than the medicinal intakes), preservation of a physical activity, fall prevention. The ability of bisphosphonate for decreasing significantly the number of fractures was proved, but the lack of lasting adhesion (persistence) and of flanking measures leads to believe their efficiency may be enhanced: the hip-fracture rate decreases from 2.1% for the non-adherents to 1,3% for the patients with observance, which represents a one-half reduction. The cost of surgery for a femoral neck fracture is estimated at 8500 euros. So the prevention of only one femoral neck fracture entails a huge economy. However, 50% of women stop their treatment before a year and the implementation of hygienic and dietary measures leads to a lifestyle change, and faces long time ingrained habits. Only 42% of patients continue their treatment after two years, and only 16% after three years.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Centre Hospitalier Régional Metz-Thionville.